BC Partners announced the sale of the majority stake in Pharmathen to the international private equity firm Partners Group. The transaction values the company at 1.6 billion euros.
Pharmathen was founded in 1969 and was acquired by BC Partners in 2015 for 475 million euros and is now the leading European company in the field of drug administration technology, the announcement said.
With a highly diversified business model and strong management team, the company specializes in the development of “extended release” technologies, with top R&D capabilities, serving a blue-chip customer portfolio in nearly 100 countries worldwide.
“Owned by BC Partners, Pharmathen has grown into a technology-driven company leading a highly attractive industry, with strong and sustainable organic EBITDA growth of 16% on a weighted annual average over the last 5 years. The company is a world leader in the field of extended release compound injection products (“LAI”), while at the same time it has created a technology platform for prolonged release treatments (“LATT”) that will fuel its growth for many years. “With a highly diversified product, customer and geographic base, Pharmathen is in a strong position to grow further, particularly in the US market, under the guidance of the Partners Group.”
Mr. Nikos Stathopoulos, Partner and Head of BC Partners said: “At Pharmathen, we saw an opportunity to make a significant investment in a high quality business to accelerate its organic growth and develop the company into a global leader. During the period of our ownership, we invested more than € 250 million in Research and Development and in new FDA approved production facilities, we almost doubled the number of employees and implemented projects that really transformed the company. This has allowed us to reposition Pharmathen as a technology-driven company in a very attractive industry with high barriers to entry, with a diversified business model, significant R&D projects in progress and top productive capabilities that give it strong prospects for greater growth. In collaboration with Management, we have built a truly admirable company, which I am convinced will continue to stand out under the management of Partners Group “.
Mr. Dimitris Kadis, CEO of Pharmathen, added: “I want to thank the BC team for their cooperation over the last six years. Their investment, support, and guidance have enabled them to be a key player in taking the company to the next level as a global leader in drug development and delivery. We are excited to partner with Partners Group in this new development chapter in our history, to build a strong drug development pillar that is a trusted partner of blue-chip customers around the world and has a positive impact on people’s lives ensuring that they can enjoy better health. ”
Consultants for BC Partners were Jefferies and Kirkland & Ellis.
The transaction is subject to obtaining the necessary regulatory approvals and is expected to be completed within 2021.
στο Google News και μάθετε πρώτοι όλες τις ειδήσειςLatest News
Greece’s Retail Sector Turnover Sees 2.4% Growth in 2024
Among the regions, the North Aegean recorded the highest turnover growth in 2024, with a 3.8% increase, followed by Attica with 3%.
Greece Reallocates Emissions Funds, Prioritizing Industry Over Consumers and Green Transition
Greece shifts €152 million in emissions funds to aid energy-intensive sectors like aluminum and steel at the expense of support for consumers, renewable energy and the green transition.
Santorini Tourism Union Demands Emergency Support Amid Cyclades Seismic Crisis
The Greek government is reportedly considering a mini support package for Santorini, to be activated if the island's seismic activity persists for an extended period.
Societe Generale Says Greek Stock Market Appealing
The French multinational bank and financial services company firm highlights notable differences in equity risk premiums between Eurozone core and peripheral countries
Greece a Safe Destination, Says Tourism Minister Kefalogianni
The Minister noted that Santorini was geologically unique, reassuring everyone that the Tourism Ministry was in close cooperation with experts to monitor the situation and take appropriate measures
Life Expectancy Rise in Europe Slows Down – Greece, UK Record Highest Declines: Lancet Medical Journal
Poor diet and lack of physical activity are seen as key factors contributing to the negative trend.
Capital Ship Management and Lloyd’s Register Complete the World’s First Tanker On-shore Power Supply Compatibility Assessment
This innovative project marks a significant step forward in the transition towards sustainable port operations
Greek Airports See 12.6% Surge in Passenger Traffic in January 2025
The steady extension of the tourist season is fueling optimism, highlighting Greece’s strong position as a top global destination
Greek Foreign Minister Gerapetritis to Meet U.S. Counterpart Rubio in the U.S.
Greek FM Gerapetritis will be in the U.S. to speak before the United Nations Security Council in New York on Monday and Tuesday, focusing on the war in Ukraine and developments in Syria.
National Bank of Greece (NBG) Stocks Remain Attractive: UBS
In this context, UBS maintains its “buy” recommendation with a price target of €11.20.
![ΑΠΕ: Ρεκόρ παραγωγής ενέργειας από ΑΠΕ στην ΕΕ το 2023 – Η θέση της Ελλάδας [γραφήματα]](https://www.ot.gr/wp-content/uploads/2025/02/ot_ape_ola-1024x600-1-90x90.png)
![Τουρισμός: Τα απανωτά ρεκόρ και ο αστερίσκος της Σαντορίνης – Το στοίχημα της σεζόν [πίνακες]](https://www.ot.gr/wp-content/uploads/2025/01/tourismos-90x90.jpg)
![ΑΠΕ: Ρεκόρ παραγωγής ενέργειας από ΑΠΕ στην ΕΕ το 2023 – Η θέση της Ελλάδας [γραφήματα]](https://www.ot.gr/wp-content/uploads/2025/02/ot_ape_ola-1024x600-1-600x352.png)
